Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.
Also called NCT06948292
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 127 participants
- Sponsor
- Ebima Clifford Okundaye
- Registry
-
NCT06948292
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06948292. Non-randomized; double masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-08-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
- Acronym
- QRX-3 in CKD
- Condition
- Chronic Kidney Disease Stages 3-5
- Condition
- Diabetic Kidney Disease
- Condition
- Hypertensive Kidney Disease
- Intervention (Drug)
- QRX-3
- Lead sponsor
- Ebima Clifford Okundaye
Record details
- Record id
cardio:ct-nct06948292- Content hash
85f1d52089eeb1fd53a1c7830f2c1cc7fc3cfc5ff546534c30369f4c72e548f8